It has been convincingly demonstrated that, in many cancers, the tumourigenic cells expressing common CSC markers, particularly CD133 and CD44, are not only resistant to commonly used anti-cancer drugs in colorectal cancer, including 5-FU and Oxaliplatin, but their number is also significantly increased after treatment [67–77]. Here, PROM1 is linked to cancer.